Systematic Review of Efficacy and Safety of Silibinin Capsules and Hugan Tablets in Improving Fatty Liver-Related Biochemical Indicators

doi:10.14009/j.issn.1672-2124.2022.01.014

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Efficacy and Safety of Silibinin Capsules and Hugan Tablets in Improving Fatty Liver-Related Biochemical Indicators

更新时间：2022-10-08

- Systematic Review of Efficacy and Safety of Silibinin Capsules and Hugan Tablets in Improving Fatty Liver-Related Biochemical Indicators
- Vol. 22, Issue 1, Pages: 64-69(2022)
- 作者机构：
  
  1. 北京医院检验科国家老年医学中心中国医学科学院老年医学研究院
  2. 北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.01.014
  CLC： R575.5
- Published：2022，
扫描看全文
Systematic Review of Efficacy and Safety of Silibinin Capsules and Hugan Tablets in Improving Fatty Liver-Related Biochemical Indicators. [J]. 22(1):64-69(2022)
DOI：

Systematic Review of Efficacy and Safety of Silibinin Capsules and Hugan Tablets in Improving Fatty Liver-Related Biochemical Indicators. [J]. 22(1):64-69(2022) DOI： 10.14009/j.issn.1672-2124.2022.01.014.

摘要

目的:基于系统评价

比较水飞蓟宾胶囊与护肝片在改善脂肪肝相关生化指标方面的有效性和安全性。方法:计算机检索万方数据库、中国生物医学文献数据库、中国知网、the Cochrane Library、Embase和PubMed等数据库

纳入水飞蓟宾胶囊与护肝片治疗脂肪肝的随机对照试验(研究组的治疗方案为水飞蓟宾胶囊

对照组为护肝片)

检索时间为建库至2021年10月。提取资料、选取文献并评价纳入文献的偏倚风险后

采用Rev Man 5.4软件进行Meta分析。结果:共纳入9篇文献

包括700例患者(研究组患者384例

对照组患者316例)。Meta分析结果显示

研究组患者的总有效率(OR=4.39

95%CI=2.95～6.55

P <0.000 01)、显效率(OR=2.27

95%CI=1.56～3.32

P<0.000 1)、治愈率(OR=2.67

95%CI=1.67～4.28

P<0.000 1)、丙氨酸转氨酶水平(MD=-12.16

95%CI=-15.06～-9.26

P<0.000 01)、天冬氨酸转氨酶水平(MD=-12.32

95%CI=-15.26～-9.39

P<0.000 01)、三酰甘油水平(MD=-0.46

95%CI=-0.69～-0.22

P<0.000 1)和总胆固醇水平(MD=-1.27

95%CI=-2.17～-0.37

P=0.006)均显著优于对照组

差异均有统计学意义;研究组患者的不良反应发生率较对照组显著降低

差异有统计学意义(OR=0.26

95%CI=0.09～0.78

P=0.02)。结论:现有证据表明

相比于护肝片

水飞蓟宾胶囊在改善脂肪肝相关生化指标方面更有效

安全性更高。因选取的文献数量和文献质量的限制

上述结论有待今后更多高质量的随机对照试验予以验证。

Abstract

OBJECTIVE: To systematically evaluate the efficacy and safety of Silibinin capsules and Hugan tablets in improving fatty liver-related biochemical indicators. METHODS: Wanfang Data

CBM

CNKI

the Cochrane Library

Embase and PubMed database were retrieved to collect the randomized controlled trials of Silybin capsule and Hugan tablets in the treatment of fatty liver（ the study group was treated with Silibinin capsules and the control group received Hugan tablets）. The retrieval time was from the establishment of the database to Oct. 2021. After extracting data

selecting literature and evaluating the risk of bias for the included literature

RevMan 5. 4 software was used for Meta analysis. METHODS: Totally 9 literature were enrolled

including 700 patients（ 384 patients in the study group and 316 patients in the control group）. Meta-analysis results showed that the total effective rate（ OR = 4. 39

95%CI =2. 95-6. 55

P<0. 000 01）

significant effective rate（ OR = 2. 27

95% CI = 1. 56-3. 32

P < 0. 000 1）

recovery rate（ OR = 2. 67

95%CI= 1. 67-4. 28

P<0. 000 1）

alanine aminotransferase（ MD =-12. 16

95%CI =-15. 06--9. 26

P<0. 000 01）

aspartate aminotransferase（ MD =-12. 32

95% CI =-15. 26--9. 39

P <0. 000 01）

triglyceride level（ MD=-0. 46

95%CI=-0. 69--0. 22

P<0. 000 1） and total cholesterol level（ MD=-1. 27

95%CI =-2. 17--0. 37

P = 0. 006） in the study group were significantly better than those in the control group

with statistically significant difference. The incidence of adverse drug reactions in the study group was significantly lower than that in the control group

the difference was statistically significant（ OR = 0. 26

95% CI = 0. 09-0. 78

P = 0. 02）. CONCLUSIONS:Available evidence suggests that Silymarin capsules are more effective and safer than Hugan tablets in improving fatty liver-related biochemical indicators. Due to the limitations of quantity and quality of the included literature

the above findings need to be validated by more high-quality randomized controlled trials in the future.

关键词

水飞蓟宾胶囊护肝片脂肪肝Meta分析随机对照试验

Keywords

Silibinin capsulesHugan tabletsFatty liverMeta-analysisRandomized controlled trials

references

查看原文

Views

273

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review on Efficacy of Silybin Capsules in the Treatment of Hepatitis

Systematic Review on Clinical Efficacy of Compound Glycyrrhizin in the Treatment of Fatty Liver

Systematic Review of Faropenem in the Treatment of Bacterial Infection

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Systematic Review of Efficacy and Safety of Dantian Jiangzhi Pills Combined with Statins in the Treatment of Hyperlipidemia

Related Author

郑子恢

高峰

赵紫楠

潘慧杰

郭思瑞

张亚同

金鹏飞

XU Yuan

Related Institution

Beijing Hospital

Dept.of Health Care, Security Bureau of the Central Military Commission Joint Staff

Dept.of Clinical Laboratory, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine of Chinese Academy of Medical Sciences

School of Pharmacy,Shaanxi University of Traditional Chinese Medicine

Central Laboratory, Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine

⁰